Popular alternative therapy for psoriasis performs no better than placeboMarch 03, 2008Anecdotal evidence touting the healing power of the Indian spice turmeric for psoriasis received a setback in a prospective study published this month by a leading dermatology journal stating that the low response rate of patients who ingested the active ingredient of the exotic spice was probably a result of the placebo effect. Researchers at the University of Pennsylvania School of Medicine found that despite strong scientific evidence in the laboratory demonstrating the ability of curcumin (the active ingredient in the spice turmeric) to inhibit a critical pathway of psoriasis, the positive response in patients was so low that scientists suggest the placebo effect or the disease's natural remission might be the reason. The study was published in the Journal of the American Academy of Dermatology. "Alternative and complementary websites and newspapers publish anecdotal reports that the Indian spice has been successfully used to treat psoriasis," says Joel M. Gelfand, MD, MSCE, of The University of Pennsylvania School of Medicine. "However, spontaneous improvements in psoriasis are common, and based on our study, until larger, placebo-controlled trials are conducted, oral curcumin should not be recommended for the treatment of psoriasis given lack of proven efficacy."
But the researchers do not discount entirely the potential of curmumin as a treatment for psoriasis. They recognize that current traditional pharmacologic approaches in the treatment of psoriasis are costly and have their limitations, including the risk of infections and possibly malignancies with long-term use resulting in many patients with the disease unable to achieve effective long-term control. Turning to complementary and alternative therapies is understandable, they say. In fact, of the estimated 7 million diagnosed with psoriasis, it is estimated that 51% use complementary and alternative medicine therapies to treat their skin. The excellent responses that were observed in two of the 12 patients in the study suggest that curcumin may have promise for a small subset of patients with psoriasis. Large, placebo-controlled trials are necessary to definitively prove or disprove oral curcumin as a potential therapeutic agent for psoriasis. "What is needed is scientific data to assess the safety and efficacy of these treatments so that we may more rationally inform patients of their treatment options," says Gelfand. University of Pennsylvania School of Medicine | |||||||||||||||||||||
|
Related Psoriasis Current Events and Psoriasis News Articles Geisinger study: PTSD causes early death from heart disease Vietnam veterans who experienced posttraumatic stress disorder (PTSD) were twice as likely to die from heart disease as veterans without PTSD, a new Geisinger study finds. Complexity of Crohn's disease revealed as 'gene' count tops 30 New research has trebled the number of genetic regions known to be implicated in Crohn's disease, a form of inflammatory bowel disease, to over thirty. Scientist study bacterial communities inside us to better understand health and disease The number of bacteria living within the body of the average healthy adult human are estimated to outnumber human cells 10 to 1. Changes in these microbial communities may be responsible for digestive disorders, skin diseases, gum disease and even obesity. Inflammation, depression and antidepressant response: Common mechanisms Major depressive disorder is a common and complex condition that impacts about 15% of the population of the United States, yet very little is known about the mechanisms behind the psychiatric disorder. Watery pools in bone marrow key to psoriatic arthritic damage Researchers have learned more about how a leading drug prevents certain types of arthritis from eating away at bone, according to a study published in the March edition of the Annals of the Rheumatic Diseases. New findings show Enbrel significantly reduced levels of C-reactive protein Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe plaque psoriasis through one year. Severe psoriasis associated with increased risk of death Patients with severe psoriasis appear to have an increased risk of death compared with patients without the skin condition, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals. Phase 3 data show golimumab improved psoriatic arthritis symptoms Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the disease. Scientists complete genome sequence of fungus responsible for dandruff, skin disorders Scientists from P&G Beauty announced that they successfully sequenced the complete genome for Malassezia globosa (M. globosa), a naturally occurring fungus responsible for the onset of dandruff and other skin conditions in humans. More Psoriasis Current Events and Psoriasis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||